Evidence map›Paper›PMID 40529212›Full record

ArticleJHEP reports : innovation in hepatology2025

DHCR7 inhibition ameliorates MetALD and HCC in mice and human 3D liver spheroids.

Gen Yamamoto, Raquel Carvalho-Gontijo Weber, Wonseok Lee, Vivian Zhang, Haeum Jang, Sadatsugu Sakane, Xiao Liu, Hyun Young Kim, David A Brenner, Na Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gen YamamotoDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Raquel Carvalho-Gontijo WeberDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Wonseok LeeDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Vivian ZhangDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Haeum JangDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Sadatsugu SakaneDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Xiao LiuDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Hyun Young KimDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
David A BrennerDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Na LiDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Tatiana KisselevaDepartment of Surgery, University of California, San Diego, La Jolla, CA, USA.

Funding

San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
Inactivation of Hepatic Stellate Cells During Reversal of Liver FibrosisR01DK099205 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRENNER, DAVID A., KISSELEVA, TATIANA · 2014 to 2025
$4.8M
The Role of Portal Fibroblasts in Cholestatic Liver FibrosisR01DK101737 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KISSELEVA, TATIANA · 2014 to 2025
$3.8M
The role of IL-17 signaling in alcohol-induced HCCR01AA028550 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRENNER, DAVID A., KISSELEVA, TATIANA · 2021 to 2025
$2.3M
The Role of IL-17 in Alcoholic Liver Disease and CancerU01AA022614 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL, KISSELEVA, TATIANA · 2014 to 2018
$1.8M
NIAAA NIH HHS R01 AA028550NIAAA NIH HHS U01 AA022614NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK099205NIDDK NIH HHS R01 DK101737
6 · The paper itself

Abstract

Background & Aims: Metabolic dysfunction and alcohol-associated liver disease (MetALD) results in the development of liver steatosis, inflammation, fibrosis, and hepatocellular carcinoma (HCC). Methods: We investigated whether targeting DHCR7 can ameliorate the development of MetALD and HCC using experimental models and 3D human liver spheroids. Results: Here, we demonstrate that partial genetic ablation of the Conclusions: Our data demonstrate that targeting DHCR7 can become a strategy for the treatment of MetALD and HCC. Impact and implications: This study demonstrates the critical role of

Indexed as

Alcohol-induced liver injuryCholesterol synthesisFibrosisInflammationSteatosisTumor growth

Identifiers

PMID40529212
PMCPMC12173064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.